<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02321189</url>
  </required_header>
  <id_info>
    <org_study_id>Sun3</org_study_id>
    <nct_id>NCT02321189</nct_id>
  </id_info>
  <brief_title>The Effect of Resveratrol Based Nutritional Supplement on Choroidal Thickness</brief_title>
  <official_title>The Effect of Resveratrol Based Nutritional Supplement on Choroidal Thickness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Choroidal thickness represents blood-flowing of eyes. The investigators detect the choroidal&#xD;
      thickness of the young participant using SD-OCT to see the effect of Resveratrol Based&#xD;
      Nutritional Supplement on Choroidal Thickness.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      34 young, healthy participants were included in this study; They were randomly divided into&#xD;
      two groups by age and gender matched.100 mg Longevinex® capsule was given to the study group&#xD;
      and 100mg placebo capsule to the control group. All participants underwent OCT scanning with&#xD;
      spectral domain optic coherence tomography (SD-OCT) at baseline and 1 h following Longevinex®&#xD;
      or placebo administration. The choroidal thickness was measured manually by the Heidelberg&#xD;
      Eye explore software(version 5.3.3.0, Heidelberg Engineering) with a vertical line to the&#xD;
      retinal pigment epithelial layer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Choroidal Thickness(micrometer)</measure>
    <time_frame>baseline</time_frame>
    <description>using Heidelberg Eye Explorer software to measure choroidal thickness of participants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Choroidal Thickness(micrometer)</measure>
    <time_frame>1 hour after baseline</time_frame>
    <description>using Heidelberg Eye Explorer software to measure choroidal thickness of participants</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Eye Disease</condition>
  <arm_group>
    <arm_group_label>LONGEVINEX</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The Effect of LONGEVINEX on Choroidal Thickness</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The Effect of placebo on Choroidal Thickness</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LONGEVINEX</intervention_name>
    <description>let everyone of the participants oral 1 capsule containing 100 mg LONGEVINEX</description>
    <arm_group_label>LONGEVINEX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>let everyone of the participants oral 1 capsule containing 100 mg placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female patients 23-28 years of age. nonsmokers.&#xD;
&#xD;
          2. Patients were considered to be healthy on the basis of electrocardiogram (ECG), and&#xD;
             clinical laboratory safety tests (haematology, plasma biochemistry, urinalysis and&#xD;
             hepatitis B, hepatitis C and HIV serology) performed at screening.&#xD;
&#xD;
          3. Avoid ingesting grapefruit, grapefruit juice or other grapefruit juice containing&#xD;
             products, and any herbal-based nutrient supplement or prescribed medications(&#xD;
             grapefruit, cranberry, blueberry products, peanuts and peanut butter, grape and grape&#xD;
             products, and red wine ) during the same period of time.&#xD;
&#xD;
          4. patients should abstain from alcohol-containing beverages at least two days prior to&#xD;
             and during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Uncontrolled Blood pressure exceeding diastolic pressure of 100 mm Hg (sitting) during&#xD;
             the screening period and uncontrolled diabetes mellitus&#xD;
&#xD;
          2. Participation in another simultaneous medical investigation or trial Renal failure&#xD;
             requiring dialysis or renal transplant or liver dysfunction History of other&#xD;
             disease,or other findings giving reasonable suspicion of a disease or condition that&#xD;
             contraindicates the use an investigational drug, might affect interpretation of the&#xD;
             results of the study, or render the subject at high risk from treatment complications.&#xD;
&#xD;
          3. IOP over 30 mmHg.&#xD;
&#xD;
          4. Any previous retinal laser photocoagulation to the study eye in treatment naive. Any&#xD;
             previous intravitreal injection in study eye (triamcinolone or other) in treatment&#xD;
             naive.&#xD;
&#xD;
          5. Any previous vitrectomy in study eye (posterior or anterior associated with vitreous&#xD;
             loss in cataract surgery).&#xD;
&#xD;
          6. Intracapsular cataract extraction (posterior capsule needs to be present).&#xD;
&#xD;
          7. Aphakia or absence of the posterior capsule in the study eye, Structural damage to the&#xD;
             center of the macula in the study eye preexisting to CRVO likely to preclude&#xD;
             improvement in visual acuity following the resolution of macular edema, including&#xD;
             atrophy of the retinal pigment epithelium, subretinal fibrosis, laser scar(s).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>23 Years</minimum_age>
    <maximum_age>28 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xunfang Sun</last_name>
    <role>Study Director</role>
    <affiliation>Department of Ophthalmology,Tongji Hospital, Tongji Medical College, Huazhong University of science and Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shuaishuai Wang</last_name>
    <phone>15623422892</phone>
    <email>949990624@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tongji Medical College of HUST</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuaishuai Wang</last_name>
      <phone>15623422892</phone>
      <email>949990624@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>November 8, 2014</study_first_submitted>
  <study_first_submitted_qc>December 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2014</study_first_posted>
  <last_update_submitted>April 2, 2015</last_update_submitted>
  <last_update_submitted_qc>April 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Xufang Sun</investigator_full_name>
    <investigator_title>study director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

